Literature DB >> 11960387

The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.

Oliver G Ottmann1, Dieter Hoelzer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960387     DOI: 10.1038/sj.thj.6200151

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


× No keyword cloud information.
  5 in total

1.  Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines.

Authors:  Yousef Najajreh; Hazem Khamaisie; Nili Ruimi; Soliman Khatib; Joshua Katzhendler; Martin Ruthardt; Jamal Mahajna
Journal:  Mol Biol Rep       Date:  2012-12-05       Impact factor: 2.316

Review 2.  Treatment of acute lymphoblastic leukaemia : a new era.

Authors:  Effrosyni Apostolidou; Ronan Swords; Yesid Alvarado; Francis J Giles
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Ectopic Expression of Snail and Twist in Ph+ Leukemia Cells Upregulates CD44 Expression and Alters Their Differentiation Potential.

Authors:  Noa Kidan; Hazem Khamaisie; Nili Ruimi; Shay Roitman; Elizabeth Eshel; Najib Dally; Martin Ruthardt; Jamal Mahajna
Journal:  J Cancer       Date:  2017-10-23       Impact factor: 4.207

4.  Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells.

Authors:  Ofer Regev; Noa Kidan; Meshel Nicola; Hazem Khamisie; Martin Ruthardt; Jamal Mahajna
Journal:  Arch Med Sci       Date:  2020-11-20       Impact factor: 3.318

5.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.